Abelcet

Cerebral Cryptococcosis, Histoplasmosis, Coccidioidomycosis + 25 more
Treatment
28 FDA approvals
20 Active Studies for Abelcet

What is Abelcet

Amphotericin BThe Generic name of this drug
Treatment SummaryAmphotericin B is a medication used to treat fungal infections. It is effective against a wide range of fungi, including Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus. Amphotericin B is not effective against bacteria, rickettsiae, or viruses. However, some species of Candida are less susceptible and Pseudallescheria boydii and F
Fungizoneis the brand name
Abelcet Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Fungizone
Amphotericin B
1966
10

Approved as Treatment by the FDA

Amphotericin B, otherwise called Fungizone, is approved by the FDA for 28 uses like severe Fungal infection caused by Conidiobolus spp. and severe Fungal infection caused by Basidiobolus spp. .
severe Fungal infection caused by Conidiobolus spp.
severe Fungal infection caused by Basidiobolus spp.
severe Mucocutaneous leishmaniasis
severe Fungal infection caused by sporotrichosis spp.
severe North American blastomycosis
Histoplasmosis
Leishmaniasis, Visceral
Sporotrichosis
Mycoses
Cryptococcosis
Febrile Neutropenia
failed previous amphotericin B treatment
Used to treat failed previous amphotericin B treatment in combination with DL-dimyristoylphosphatidylcholine
severe Histoplasmosis
Visceral Leishmaniasis
severe Cryptococcosis
severe Systemic candidiasis
Mucocutaneous Leishmaniasis
Meningitis, Cryptococcal
Febrile Neutropenia
Leishmaniasis, Cutaneous
Gilchrist Disease
Coccidioidomycosis
Systemic candidiasis
Leishmaniasis, Mucocutaneous
Mycoses
Cerebral Cryptococcosis
HIV
Invasive Fungal Infections

Effectiveness

How Abelcet Affects PatientsAmphotericin B is an antifungal medication that is effective in treating many species of fungi, including Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus. While Candida albicans is usually sensitive to this drug, other species may not be as affected. Pseudallescheria boydii and Fusarium species are usually resistant to amphotericin B
How Abelcet works in the bodyAmphotericin B works by attacking the cell membrane of fungal organisms, causing it to become permeable and leak its contents. The drug binds to the sterol ergosterol, which is the main sterol contained in the fungal cell membrane. This bond is irreversible, leading to the destruction of the cell and death of the fungus.

When to interrupt dosage

The suggested measure of Abelcet is predicated upon the diagnosed state, including Aspergillosis, severe Cryptococcosis and severe Mucocutaneous leishmaniasis. The amount of dosage fluctuates, as per the administration technique mentioned in the table below.
Condition
Dosage
Administration
Cerebral Cryptococcosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Tuberculosis, Osteoarticular
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Aspergillosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Gilchrist Disease
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Coccidioidomycosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Systemic candidiasis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Mycoses
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Aspergillosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Cystitis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Histoplasmosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Leishmaniasis, Cutaneous
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Mycoses
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Sporotrichosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
failed previous amphotericin B treatment
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Leishmaniasis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Cryptococcosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Histoplasmosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Coccidioidomycosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Cryptococcosis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical
Endophthalmitis
, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Intravenous, Powder, for suspension, Cream - Topical, Lotion - Topical, Injection - Intravenous, Injection, Suspension - Intravenous, Suspension, Topical

Warnings

There are 20 known major drug interactions with Abelcet.
Common Abelcet Drug Interactions
Drug Name
Risk Level
Description
Cyclosporine
Major
Amphotericin B may increase the nephrotoxic activities of Cyclosporine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neomycin.
Tenofovir
Major
Amphotericin B may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.
Abelcet Toxicity & Overdose RiskThe lowest toxic dose of amphotericin B for rats is greater than 5 gm/kg. Overdosing on this drug can lead to a halt in breathing and heart function.

Abelcet Novel Uses: Which Conditions Have a Clinical Trial Featuring Abelcet?

Ten active clinical trials are being conducted to assess the potential of Abelcet to address Meningitis, Fungal Histoplasmosis and Fungal Infections.
Condition
Clinical Trials
Trial Phases
Tuberculosis, Osteoarticular
0 Actively Recruiting
Coccidioidomycosis
0 Actively Recruiting
Cerebral Cryptococcosis
1 Actively Recruiting
Phase 2, Phase 3
Mycoses
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Cryptococcosis
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Meningitis, Fungal
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Systemic candidiasis
4 Actively Recruiting
Phase 3, Phase 2
Febrile Neutropenia
3 Actively Recruiting
Phase 2, Not Applicable
Cryptococcosis
0 Actively Recruiting
talaromycosis
0 Actively Recruiting
Leishmaniasis, Cutaneous
0 Actively Recruiting
Invasive Fungal Infections
3 Actively Recruiting
Phase 3, Phase 2
Endophthalmitis
0 Actively Recruiting
Mycoses
0 Actively Recruiting
Leishmaniasis, Mucocutaneous
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Gilchrist Disease
0 Actively Recruiting

Patient Q&A Section about abelcet

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How to Administer Abelcet?

"The recommended daily adult and child dosage of ABELCET® is 5 milligrams per kilogram given in a single infusion. ABELCET® should be administered by intravenous infusion at a rate of 2.5 milligrams per kilogram per hour. If the infusion time exceeds two hours, mix the contents of the infusion bag by shaking it every two hours."

Answered by AI

Who makes Abelcet?

"(n.d.). Retrieved May 20, 2021, from https://leadiantbiosciences.com/products/abelcet-b-lipid-complex-injection/

Leadiant Biosciences manufactures Abelcet, a lipid complex injection used to treat fungal infections. Abelcet is available in the United States."

Answered by AI

What is Abelcet used for?

"This medication is used to treat a variety of serious fungal infections. It is often used in patients who cannot tolerate or who do not respond to the regular amphotericin treatment. It works by stopping the growth of fungi."

Answered by AI

What is the generic name for Abelcet?

"Abelcet is used to treat a variety of serious fungal infections. It is an antifungal antibiotic."

Answered by AI

Clinical Trials for Abelcet

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Abelcet clinical trials? We made a collection of clinical trials featuring Abelcet, we think they might fit your search criteria.Go to Trials
Have you considered Abelcet clinical trials? We made a collection of clinical trials featuring Abelcet, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Abelcet clinical trials? We made a collection of clinical trials featuring Abelcet, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security